We prospectively studied 244 consecutive patients with subarachnoid hemorrhage who were admitted within 72 hours to the same institution between November 1977 and May 1987 and who were not treated with antifibrinolytics. From November 1977 through December 1982 (the first study period), daily fluid intake was 1.5-2 1 and fluid restriction was applied when hyponatremia developed; antihypertensives were administered to all patients with high blood pressure. From January 1983 through April 1987 (the second study period), daily fluid intake was at least 3 1, fluid restriction was not applied, and antihypertensives were administered only when patients were receiving this treatment before admission; calcium antagonists were not administered. Entry variables of the patients admitted during the two study periods were not significantly different, although patients admitted during the second study period were at slightly increased risks of developing cerebral ischemia and of having a poor outcome. Despite this, cerebral ischemia occurred less frequently among patients admitted during the second study period than among those admitted during the first (16 [10%] of 155 patients vs. 19 [21%] of 89 patients; ^=0.030). Overall mortality decreased from 46% to 36% while mortality among patients with cerebral ischemia decreased from 60% to 31% (difference not significant). Rebleeding and acute hydrocephalus occurred with the same frequency among patients admitted during both study periods. We conclude that the combination of increased fluid intake and the avoidance of antihypertensives helps prevent cerebral ischemia after subarachnoid hemorrhage. (Stroke 1989;20:1511-1515)
C erebral ischemia is a major complication after subarachnoid hemorrhage (SAH).
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Recently, it has been suggested that volume status is important in the development of cerebral ischemia. 34 Patients with hyponatremia after SAH had an increased risk of developing cerebral ischemia when treated with fluid restriction. 5 Case reports described improvement of clinical deficits attributed to cerebral ischemia after plasma volume expansion. 4 -6 - 7 In addition, induced hypertension may also reverse symptoms of cerebral ischemia. 8 These observations prompted us to change our management of patients with SAH. Before 1983, daily fluid intake was 1.5-2 1 and antihypertensives were administered when hypertension developed. Moreover, fluid restriction was applied in case of hyponatremia, on the (incorrect) assumption that low serum sodium levels were caused by dilution (inappropriate secretion of antidiuretic hormone) rather than by sodium loss. After January 1983, daily fluid intake was at least 3 1, fluid restriction was not applied, and antihypertensives were administered only when a patient was receiving this treatment before admission.
A randomized clinical trial is the best method to compare the effects of these different management regimens on cerebral ischemia and outcome. However, in view of our previous analysis, 5 we felt that it was no longer ethical to randomize patients to treatment with fluid restriction and low daily fluid intake. To assess the effect of the new treatment regimen on cerebral ischemia and on outcome in general, we compared the management results of patients treated before 1983 with results of those patients treated after 1982. 
Subjects and Methods
We prospectively studied 384 consecutive patients with the clinical features of SAH, confirmed by initial computed tomography (CT scan) on admission. 9 Treatment with tranexamic acid is an important variable related to cerebral ischemia, 110 -11 and since treatment with tranexamic acid differed among these 384 patients (patients received longterm tranexamic acid treatment or placebo before 1983 11 and short-term tranexamic acid or no treatment after 1982), our analysis of the effect of the different regimens on cerebral ischemia and outcome was restricted to the 244 patients who did not receive tranexamic acid. Patients with negative angiograms or with evidence on the initial CT scans of SAH other than ruptured aneurysm were not included. 12 -13 All patients were admitted <72 hours after the initial SAH to the Department of Neurology of the University Hospital Rotterdam (from November 1977 until May 1987). If death appeared imminent, entry into the study was delayed.
During the observation period, which lasted 4 weeks or until death or surgery, all patients were under continuous observation in an intensive care unit. The level of consciousness was assessed by means of the 14-point Glasgow Coma Scale 14 ; a score >12 indicated a good clinical condition. Most operations were carried out on Day 12 after the presenting SAH. When a patient's clinical condition deteriorated, physical examination and CT were repeated. Outcome was assessed after 3 months, according to the 5-point Glasgow Outcome Scale. 15 In 185 (76%) of the 244 patients, an aneurysm was demonstrated by angiography or by postmortem examination. In the remaining 59 patients, angiography and surgery were not considered because of advanced age or impaired level of consciousness. However, in these patients rupture of an aneurysm was considered highly probable because CT showed extravasation in the interhemispheric, suprasellar, or sylvian cisterns without evidence of other causes of SAH. 12 The amount of cisternal blood on the initial CT scan was graded on a scale of 0 to 3 separately for each of the 10 cisterns (maximum sum score 30) as previously described. 10 - 16 Similarly, intraventricular blood was graded separately for each ventricle (maximum score 12). 10 
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ls Because an intraventricular score of 1 reflects sedimentation of blood in the ventricle, we considered only a score of >1 for at least one of the four ventricles to be relevant, and we referred only to this as "presence of intraventricular blood."
Clinical events were defined as 1) probable delayed cerebral ischemia: gradual development of focal neurologic signs, with or without deterioration in the level of consciousness, without confirmation by CT or autopsy; 2) definite delayed cerebral ischemia: deterioration in the level of consciousness or development of focal signs, or both, with CT or autopsy confirmation of cerebral infarction;
3) probable rebleeding: sudden deterioration and death without the possibility of confirmation by CT or if autopsy was refused; 4) definite rebleeding: sudden deterioration with an increased amount of blood on repeat CT scan or at autopsy compared with a previous CT scan; 5) During the first study period, daily fluid intake was 1.5-2 1 and the patients were treated with fluid restriction (< 1,000 ml/day) in case of hyponatremia, defined as a sodium level of <134 mmol/1 on at least 2 consecutive days. The rationale for fluid restriction was the (incorrect) assumption that hyponatremia was caused by inappropriate secretion of antidiuretic hormone. 5 During the second study period, from January 1983 through April 1987, daily fluid intake was at least 3 1 in all patients and fluid restriction or diuretic medication after admission was avoided. Unless the patient was receiving antihypertensives on admission, such treatment was not given. When signs of cerebral ischemia developed, extra fluid (20% albumin) was administered.
The 4x4 contingency tables were analyzed with Yates' corrected \ 2 t e s t -If a n expected value was <5, the 4x4 tables were analyzed with Fisher's two-sided exact probability test.
Results
Entry variables related to the occurrence of cerebral ischemia and poor outcome at 3 months are the score on the Glasgow Coma Scale, the amount of cisternal blood on CT scan, 1 -10 the presence of intraventricular blood on CT scan, 10 and hydrocephalus on CT scan.
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14 These variables are shown separately for patients admitted during the two study periods in Table 1 . Patients admitted during the second study period had more cisternal blood and more often had intraventricular blood on the initial CT scan than those admitted during the first study period. The frequency of hyponatremia among the 155 patients admitted during the second period was 35%, and the frequency of fluid-restricted hyponatremia among the 89 patients admitted during the first period was 33%. Antihypertensive treatment was administered in nine (6%) of the 155 patients admitted during the second period and in 52 (58%) of the 89 patients admitted during the first period.
Despite the presence of more cisternal blood and the higher frequency of intraventricular blood on the initial CT scan, the occurrence of cerebral ischemia was lower among patients admitted during the second period (16 Table 2 ). This led to a slightly better outcome among patients admitted during the second period, but the difference is not significant (* 2 =2.629, p=0.104; Table 2 ). The frequency of cerebral ischemia among patients in a Table 3 ). The other major complications (rebleeding and acute hydrocephalus) occurred with the same frequency in all 244 patients and in patients with ischemia admitted during both periods (Tables 2 and 3 ). Outcome in all 244 patients and in patients with cerebral ischemia was better during the second period, whereas the incidence of other complications in these patients was not different (Tables 2 and 3) .
Mortality after 3 months in patients with cerebral ischemia (analysis restricted to patients without rebleeding) among the patients admitted during the second period was lower than that among those Analysis restricted to patients without rebleeding for cerebral ischemia and to patients without cerebral ischemia for rebleeding.
admitted during the first period (Table 4 ), but the difference was not significant (^2=1.362, /?=0.243). Mortality among patients with rebleeding (analysis restricted to patients without cerebral ischemia) and among patients with acute hydrocephalus did not differ between periods (Table 4) .
Discussion
A change in the management of patients with SAH, consisting of increased daily fluid intake and restriction of the use of antihypertensives, significantly decreased the occurrence of cerebral ischemia between study periods. The outcome of patients who developed cerebral ischemia and of all patients improved, although not significantly. The occurrence and mortality of other major complications (rebleeding and acute hydrocephalus) did not change.
In a nonrandomized study such as ours, it is important to investigate whether variables related to cerebral ischemia and to poor outcome were equally distributed between the two periods. Patients admitted during the second period not treated with tranexamic acid in whom the effects of the different management regimens were investigated were at a higher risk of developing cerebral ischemia. Despite this, the observed frequency of cerebral ischemia among these patients was lower. Moreover, all 244 consecutive patients were prospectively studied in the same institution and the entry criteria, the assessment of clinical deterioration, and the assessment of outcome had not changed over time. The additional treatment regimen had not changed; in particular, nimodipine (which has recently been demonstrated to be effective in patients after SAH 18 ) and other calcium antagonists were not administered. Therefore, we attribute the decreased occurrence of cerebral ischemia during the second period to the combination of increased daily fluid intake and the restricted use of antihypertensives.
We do not know whether the same results can be achieved by a restricted use of antihypertensives or by a large daily fluid intake alone. It has been suggested that either plasma volume expansion or artificially increased blood pressure may reverse the clinical symptoms of cerebral ischemia. 4 -6 -8 It may be that the combination of these two measures is even more effective. How an improved volume status prevents cerebral ischemia after SAH is not known. Cardiac output may increase or blood viscosity may decrease; both may result in an increased cerebral blood flow. 7 During the second period, with the exception of nine patients, we did not administer antihypertensives in patients who were not receiving this treatment before admission. A rise in blood pressure may be a compensatory mechanism to increase perfusion pressure in the presence of arterial spasm or cerebral ischemia. If this compensation exists, the harmful effect of antihypertensives would be explained. On the other hand, since blood flow in the proximal basal arteries (where the aneurysm is located) would seem to be unimpaired, hypertension might result in a higher frequency of rebleeding. Nevertheless, the frequency of rebleeding in our series remained unchanged with a restricted use of antihypertensives during the second period.
During the second period, the occurrence of cerebral ischemia among patients who were in a good grade on admission (Glasgow Coma Scale score of > 12) was remarkably low (8%). This means that the administration of calcium antagonists 18 in this subgroup of patients can hardly improve outcome by further diminishing the risk of cerebral ischemia. Calcium antagonists may be particularly beneficial to patients at an increased risk of developing cerebral ischemia, such as patients with a Glasgow Coma Scale score of <12 on admission and those who are treated with antifibrinolytic agents. Even short-term treatment with tranexamic acid increases the occurrence of cerebral ischemia (unpublished data).
In conclusion, our study strongly suggests a beneficial effect of a regimen of increased daily fluid intake and restricted use of antihypertensives in patients after SAH. From a theoretical point of view a study with randomized controls would have provided stronger evidence, but in view of our earlier finding that both fluid restriction and antihypertensive treatment are probably harmful, 5 we did not feel justified in continuing that regimen in our patients.
